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Abstract
Background Sporadic multiglandular disease (MGD) has
been reported in literature in 8–33 % of patients with primary
hyperparathyroidism (pHPT). This paper aimed to review
controversies in the pathogenesis andmanagement of sporadic
MGD.
Methods A literature search and review was made to evaluate
the level of evidence concerning diagnosis and management
of sporadic MGD according to criteria proposed by Sackett,
with recommendation grading by Heinrich et al. and Grading
of Recommendations, Assessment, Development and Evalu-
ation (GRADE) system. Results were discussed at the 6th
Workshop of the European Society of Endocrine Surgeons
entitled ‘Hyperparathyroidism due to multiple gland disease:
An evidence-based perspective’.
Results Literature reports no prospective randomised studies;
thus, a relatively low level of evidence was achieved. Appro-
priate surgical therapy of sporadic MGD should consist of a
bilateral approach in most patients. Unilateral neck explora-
tion guided by preoperative imaging should be reserved for
selected patients, performed by an experienced endocrine sur-
geon and monitored by intraoperative parathormone assay
(levels of evidence III–V, grade C recommendation). There
is conflicting or equally weighted levels IV–V evidence
supporting that cure rates can be similar or worse for sporadic
MGD than for single adenomas (no recommendation). Best
outcomes can be expected if surgery is performed by an ex-
perienced parathyroid surgeon working in a high-volume cen-
tre (grade C recommendation). Levels IV–V evidence sup-
ports that recurrent/persistence pHPT occurs more frequently
in patients with double adenomas hence in situations where a
double adenoma has been identified, the surgeon should have
a high index of suspicion during surgery and postoperatively
for the possibility of a four-gland disease (grade C
recommendation).
Conclusions Identifying preoperatively patients at risk for
MGD remains challenging, intraoperative decisions are im-
portant for achieving acceptable cure rates and long-term fol-
low-up is mandatory in such patients.
Keywords Sporadic primary hyperparathyroidism .Multiple
gland disease . Double parathyroid adenoma .
Lithium-induced hyperparathyroidism . Parathyroidectomy
Introduction
Patients with primary hyperparathyroidism (pHPT) typically
have elevated serum calcium values due to excessive secretion
of parathyroid hormone (PTH) from enlarged parathyroid
gland(s), with inappropriate cellular regulation of the PTH
secretion. pHPT is caused by a single, benign adenoma in
80–85 % of cases and by parathyroid hyperplasia or multiple
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adenomas (multiglandular disease) in 10–15 %, with rare oc-
currence of parathyroid carcinoma (<1 %). In a small group of
patients (<10 %), pHPT occurs as part of a familial genetic
syndrome, most commonly multiple endocrine neoplasia syn-
drome type 1 (MEN-1), more rarely multiple endocrine neo-
p l a s i a t y p e 2 (MEN-2 ) a nd o c c a s i o n a l l y t h e
hyperparathyroidism-jaw tumour (HPT-JT) syndrome [1]. Al-
though pHPT secondary to a known inherited genetic predis-
position is likely to be due to synchronous or metachronous
development of multiple adenomas on a background of gen-
eralised parathyroid hyperplasia, in clinical practice the ma-
jority of MGD are apparently sporadic [2]. A number of nu-
tritional, metabolic and pharmacologic disturbances that alter
parathyroid chief cell responsiveness are increasingly being
recognised [2]. Some of these lead to reversible changes in
the release of PTH. Some, however, appear to induce a more
durable dysregulation in PTH homeostasis leading to the de-
velopment of sporadic MGD [3]. This paper aimed to review
controversies in the pathogenesis andmanagement of sporadic
MGD.
Methods
A review was performed from a literature search (PubMed)
concerning diagnosis and management of patients with spo-
radic pHPT caused by MGD. The PubMed search included
articles published in the English language during recent years.
Effort was made to evaluate the level of evidence to be able to
depict current knowledge and new concepts of interest. Level
of evidence grading was done according to criteria proposed
by Sackett [4], with grading of recommendation proposed by
Heinrich et al. [5], and the Grading of Recommendations,
Assessment, Development and Evaluation (GRADE) system
[6]. According to Sackett’s classification, the strength of a
recommendation was graded ‘A’ when supported by studies
with a level of evidence I (meta-analysis or large randomised
trials with clear cutoff results and low risk for error); ‘B’when
supported by level II studies (small randomised trials and
moderate to high risk for error); ‘C’ when supported by level
III (nonrandomized, prospective with contemporaneous con-
trols trials), level IV (non-randomised trials with historical
controls, retrospective analysis) or level V studies (case series
without controls, expert opinion). In the GRADE system, the
strength of recommendations has been defined as ‘strong’, or
‘weak’; the quality of the evidence has been indicated by
crossfilled circles: ‘⊕OOO’ denotes very low quality evi-
dence (any estimate of effect is very uncertain); ‘⊕⊕OO’,
low quality (further research is very likely to have an impor-
tant impact on confidence in the estimate of effect and is likely
to change the estimate); ‘⊕⊕⊕O’, moderate quality (further
research is likely to have an important impact on confidence in
the estimate of effect and may change the estimate); and
‘⊕⊕⊕⊕’, high quality (further research is very unlikely to
change the confidence in the estimate of effect).
Results
Incidence of multiglandular disease in sporadic primary
hyperparathyroidism
The real incidence of MGD is difficult to be defined because
its estimates are influenced by several factors including the
extent of parathyroid surgery (i.e. use of routine bilateral neck
exploration (BNE) or limited scan-directed uni-compartmen-
tal exploration), the experience and confidence of the operat-
ing surgeon to identify MGD and the experience of the pa-
thologist to differentiate a (micro)adenoma from a normal
gland.
Historically, it was considered that up to one in five patients
with pHPT might have MGD. A large retrospective review of
866 consecutive BNE operated between 1960 and 1997 re-
ported that a single adenoma was present in 77 % of patients
and hyperplasia in 21 % [7]. Similarly, in a comparative study
of two American centres, MGDwas reported in 16.5% of 395
patients who underwent routine BNE and in 11 % of patients
treated with focused scan-directed parathyroidectomy as the
preferred strategy [8]. It is now accepted that even in patients
with concordant imaging suggestive of a single adenoma, fur-
ther enlarged glands could be encountered if those patients
undergo formal BNE. With such a protocol applied to 350
patients, additional abnormal parathyroid glands were found
on complete exploration in 15 % of patients with concordant
sestamibi and ultrasound [9]. A slightly lower rate of 10 %
was observed in a RCT of 46 patients, of whom 2 of 23 who
had BNE were found to have an unsuspected additional en-
larged contralateral parathyroid opposite to the site of the
scan-localised adenoma [10]. In this context, it is not surpris-
ing that five most recent series published had a wide variable
incidence of MGD ranging from 2.4 to 34 %, with variable
figures over separate time periods reported even from the
same centre (Table 1) [11–18].
These contrasting figures raise into question the clinical
significance of these additional enlarged glands. If all these
enlarged glands would be functionally significant, the failure
rate of minimally invasive parathyroidectomy (MIP) should
be much higher than the reported figures (Table 2) [19–21].
This paradox was confirmed by a comparative study between
two centres undertaking routine BNE or focused parathyroid-
ectomy, and despite their contrasting approaches, there was no
statistically significant difference in their operative success: 9
of 395 (2.3 %) patients at institution A remained hypercalce-
mic postoperatively compared with 15 of 405 (3.7 %) at insti-
tution B (p=0.24) [8].
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Pathogenesis of sporadic multiglandular disease
Definition of sporadic multiglandular disease
There are no reliable histologic criteria to consistently distin-
guish between normal, hyperplastic, and adenomatous para-
thyroid glands. Many authors conclude that the microscopic
classification of abnormal parathyroid glands as hyperplasia
or adenoma correlates poorly with the macroscopic appear-
ance. Nevertheless, the pathologist can distinguish normal
from abnormal parathyroid glands with a fair degree of accu-
racy. Therefore, over the years, surgeons have learned to rely
on a visual gross assessment of weight, size, colour and firm-
ness during surgery to separate the various types of pathologic
involvements. A practical rule for many endocrine surgeons is
that an enlarged gland is probably pathological and
hypersecreting, but this may not always be true (vide infra).
Two discrete forms of abnormal parathyroid growth have
been recognised to date; the uniglandular and the
multiglandular. Uniglandular enlargement (i.e. in the presence
of three remaining normal glands) represents the underlying
pathology in the majority of patients, varying from 75 to 95%
of all series with pHPT. In MGD, more than one gland is
involved either synchronously or asynchronously. Hyperpla-
sia involving all four glands is the majority of pathology in
MGD but two- to three-gland hyperplasia can also occur. In
addition to these two entities, some consider that multiple
adenomas represent a separate clinical entity but others argue
that multiple adenomas do not exist and instead represent
asymmetrical four-gland hyperplasia [22].
Overall, the incidence of sporadic MGD, including both
multiple adenomas and hyperplasia, varies between 7 and
33 % (Table 1) [11–18].
Several attempts have been made to address the question of
whether the level of PTH (or other clinical/biochemical pa-
rameter) can predict or define single-gland disease or MGD.
Including variables such as serum calcium and PTH levels,
results of localization studies with sestamibi and ultrasound,
some studies have reported a good positive prediction value if
several of these criteria are met [23], but this has not been
reproduced in all studies.
Many surgeons use the observed size of a parathyroid
gland as an indicator of hypersecretion. This notion is based
on the excellent success and low recurrence rates achieved by
excising all visually enlarged parathyroid glands during
surgery.
Many studies have tried to identify pathological criteria to
distinguish between normal parathyroid tissues, adenoma and
hyperplasia. Traditionally, the presence of a rim of normal
parathyroid tissue adjacent to an encapsulated nodule has been
the ‘gold standard’ for the diagnosis of a parathyroid adenoma
(Fig. 1). However, a rim of normal parathyroid tissue is not
always present and other histological characteristics have been
suggested such as fibrous capsule, cellular pleomorphism,
Table 1 Incidence of multigland disease in recent cohorts of patients undergoing bilateral neck exploration
Reference (year) Period, centre, operative strategy Total number
of patients
Double adenomas Multigland hyperplasia
Alhefdhi et al. [11] 2001–2013, University of Wisconsin, USA 1402 124 (9 %) 181 MGD (13 %)
Vandenbulcke et al. [12] 1993–2010, University Hospitals Leuven, Belgium, BNE 698 46 (6.6 %) 17 (2.4 %)
Mazeh et al. [13] 2001–2010, University of Wisconsin, USA, BNE 1235 100 (8 %) 135 (11 %)
Schneider et al. [14] University of Wisconsin, USA 1049 overt PHPT 148 (14.1 %)
388 mild PHPT 133 (34.3 %)
Hughes et al. [15] Ann Arbor, USA, focused parathyroidectomy
with MGD discovered intraoperatively
1855 207 (11 %)
Cayo et al. [16] 2000–2008, University of Wisconsin, USA 755 163 (21.5 %)
Szabo et al. [17] Uppsala University Hospital, Sweden, BNE 659 77 (11.7 %) 53 (8.0 %)
Attie et al. [18] Long Island Jewish Medical Centre, USA, BNE 865 33 (3.8 %) 46 (5.3 %)
MGD multiglandular disease, PHPT primary hyperparsathyroidism, BNE bilateral neck exploration
Table 2 Multiglandular disease as a cause of failed minimally invasive parathyroidectomy
Ref Centre Total number of patients Failure rate Cause of failure
Lee et al. [19] MD Anderson, USA 357 19 (3.5 %) 9 MGD
Bagul et al. [20] Sheffield, UK 541 25 (5 %) 13 MGD (2.5 %)
Suliburk et al. [21] University of Sydney, Australia 1020 23 (2.2 %) 10 DA, 3 MGD
MGD multiglandular disease, DA double adenoma
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presence of nodules and mitotic figures [22, 24]. In addition, it
has been shown that lipid staining may distinguish between
hyperfunctioning glands from normal parathyroid tissue [25].
In normal, or suppressed, glands, chief cells exhibit abundant
intracytoplasmic coarse and fine neutral lipid droplets. In hy-
perfunctioning tissue, droplets of intracytoplasmic neutral lip-
id are virtually absent [26]. Lastly, single adenomas are mono-
clonal lesions arising from a single precursor [27] andMGD is
probably polyclonal hence they represent two different
diseases.
Double parathyroid adenomas
Double adenomas are considered to be a distinct clinical entity
in-between uniglandular disease and multiglandular hyperpla-
sia. It has been a matter of intense debate whether double
adenomas represent a form of asynchronous four-gland hyper-
plasia. However, considering the high long-term cure rate of
two-gland resection equivalent to uniglandular disease is the
best evidence of double adenoma as a separate disease. A
biopsy from a normal parathyroid gland is considered by
many as mandatory in order to confirm the pathology present,
especially in cases with multiple adenomas.
The reported incidence of double adenomas varies widely
between 2 and 11 % [11–18].
Several attempts have been made to investigate if double
adenoma has a different clinical pattern compared with a sin-
gle adenoma and hyperplasia. Despite intensive research, no
differences between patients with double adenomas and other
patients with pHPT with regard to age, preoperative serum
calcium and PTH levels have been established [11, 12, 28].
Lithium-associated hyperparathyroidism
Lithium compounds are being used in long-term treatment of
psychiatric diseases mainly as mood-stabilising drug and in
the treatment of bipolar disorders. The mechanism of lithium-
associated hyperparathyroidism (LAH) is not well under-
stood. Many different variants of lithium salts exist, and upon
ingestion, it is rapidly absorbed in the gastrointestinal channel
and widely distributed in the body [29]. Lithium might direct-
ly stimulate PTH production. Alternatively, lithium presum-
ably interferes with calcium-mediated transmembrane signal
transduction by the calcium-sensing receptor, because it in-
duces a reduction in the set point for PTH secretion. The
similarity between lithium-induced hypercalcemia and famil-
ial hypocalciuric hypercalcemia (FHH), which is associated
with inactivating mutations in the gene encoding the calcium-
sensing receptor, has been underlined [30]. However, the ex-
act interaction between lithium and the calcium-sensing recep-
tor is unknown.
The prevalence of LAH varies greatly in literature from 2.7
to 23.2 % [31, 32]. The most recently published study showed
a prevalence of 8.6 % for LAH [33]. The definitions used and
the length of exposure to lithium can at least partly, explain the
discrepancies. Though the majority of these patients (ap-
proximately 50 %) have a single parathyroid adenoma,
there is a higher incidence of multiple adenomas com-
pared with the ordinary pHPT patient cohort [33–36].
Many hypotheses on the underlying mechanism of
LAH have been proposed including: increased threshold
of the calcium-sensing receptor, increased secretion of
the PTH, decrease of calcium uptake, inhibition of ac-
tion of glycogen synthase kinase 3b and reduction of
PTH gene transcription [37].
Is sporadic multiglandular disease a synchronous
or metachronous disease?
The majority of cases with multiple parathyroid adenomas are
likely synchronous. This notion is based on the observation
that few patients have a recurrent disease after a successful
parathyroidectomy. However, detailed analysis of a large co-
hort of patients with pHPT by Alhefdhi and co-workers
showed that the rate of persistent disease was higher among
patients with double adenomas [11]. The same authors also
showed that patients with double adenomas recur at a higher
rate compared with patients with single adenoma and hyper-
plasia [11].
Fig. 1 Gross macroscopic photo of a parathyroid adenoma (a) and four-
gland hyperplasia (b). a Right, microscopic section of parathyroid
adenoma and a normal rim. In many cases, but not all, histopathological
sections in parathyroid hyperplasia show nodules containing chief and
oxyphilic cells (right in (b)). Photos are shown owing to courtesy of
pathologist Dr. Christofer Juhlin, Karolinska Institutet, Sweden
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Risk factors of sporadic multiglandular disease
Age and gender
Only a few studies have specifically addressed the question of
whether there are any differences in age and gender between
single and double adenomas and hyperplasia. There are re-
ports that patients with persistent or recurrent hyperparathy-
roidism caused by double adenoma are older and have differ-
ent clinical manifestations [38], whereas other studies failed to
show any differences [11, 12, 28]. However, patients with
four-gland hyperplasia tended to be younger when compared
with patients with parathyroid adenoma(s), but these differ-
ences were not significant. To summarise, present data do not
support any differences with respect to gender, age and pre-
operative serum calcium and PTH levels between
uniglandular disease and MGD.
Radiation
Several cohort studies have shown that radiation towards the
neck area increases the risk for pHPT [39, 40], whereas others
have failed to do so [41]. Recently, Boehm and Dietrich
showed that up to 25 % of 61 liquidators, or cleanup workers,
had signs of hyperparathyroidism 14 years after the nuclear
plant accident in Chernobyl [42]. The risk of pHPTassociated
with radiation exposure in this cohort of liquidators was sig-
nificantly higher (p<0.001) when compared with the overall
prevalence of pHPT in a non-exposed background population
(as reported for incidence in the US population in 2001), with
an odds ratio of 63.4 (95 % CI, 35.7–112.5) [42]. However,
these studies do not report the outcome after parathyroidecto-
my, and there is no information whether radiation-induced
hyperparathyroidism has an increased prevalence of MGD.
Tezelman and co-workers reported no differences in hyperpla-
sia or double adenoma between sporadic and radiation-
induced hyperparathyroidism [43]. Taken together, it is fair
to conclude that ionising radiation is capable of inducing para-
thyroid neoplasms, but the discrepancy between studies most
likely reflects the diversity of radiation type, targeted organs,
doses and the observation interval.
Are there any other known risk factors for sporadic
multiglandular disease?
There are a number of known risk factors for hyperparathy-
roidism, like chronic renal failure, vitamin D deficiency, lith-
iummedication and less commonly chronic pancreatitis, small
bowel disease and malabsorption-dependent bariatric surgery.
These diseases are classified as secondary HPT to denote a
known cause of hyperparathyroidism.
As discussed above, several studies failed to identify any
correlation between MGD and symptoms, age, serum calcium
and PTH levels, nor clinical presentation. However, it is ten-
tative to speculate that pHPTwith multiglandular involvement
is caused by an underlying signal yet to be elucidated, espe-
cially for four-gland hyperplasia. But, also for multiple ade-
nomas, it seems unlikely that two neoplasms occurs sponta-
neously. Considering the risk of a pHPT in a cohort of patients
is 2–3 %. By pure chance, the risk of developing two adeno-
mas in the same cohort should be less than 0.1 %, i.e. several
fold lower than the observed incidence hence their occurrence
is not due to chance.
Preoperative diagnosis of sporadic multiglandular
disease
Can sporadic multiglandular disease be diagnosed
preoperatively?
Parathyroid glands can be imaged with multiple modalities,
including scintigraphy, high-resolution ultrasonography (US),
thin-section computed tomography (CT) and magnetic reso-
nance imaging (MRI) [44]. US and parathyroid scintigraphy
with methoxyisobutylisonitrile (sestamibi) are the dominant
imaging techniques used in the setting of pHPT. Sestamibi
(with pinhole collimator plus early/late acquisition) is the rec-
ommended first test, but US by an experienced investigator
(radiologist, endocrinologist, surgeon) is an alternative [45].
The second test (sestamibi or US) is used to confirm the result
of the first investigation. CT and MRI are generally useful
additional imaging modalities in the case of ectopic mediasti-
nal parathyroid adenomas since they provide detailed anatom-
ical localization of ectopic mediastinal lesions for surgical
planning [46].
Evaluation of patients with combined modalities is gaining
clinical importance [45]. Combined interpretation of scintig-
raphy and US, or scintigraphy and CT, can improve the diag-
nostic interpretation of parathyroid scintigraphy and clinical
decision making [47]. Several investigators confirmed that
sporadic MGD cannot be diagnosed preoperatively due to
low accuracy, sensitivity and specificity of any preoperative
localisation tests performed [48–62]. In particular, routine
sestamibi scintigraphy and US alone or combined do not reli-
ably predict MGD [44, 46–49, 52, 63].
Negative preoperative localization studies are highly pre-
dictive of MGD. A study investigated whether negative local-
ization studies select a specific population of patients [23].
Patients with negative preoperative study results had a high
risk of MGD (31.6 %) compared with patients with one pos-
itive study result (3.6 %) and those with two concordant pos-
itive study results (0.0 %; p<0.001) [63]. Moreover, if the
diagnosis of pHPT remains unequivocal the persistent or re-
current disease is more likely due to parathyroid hyperplasia
than solitary adenoma [45].
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Several authors have explored the possibility of predicting
pre- or intraoperatively the presence ofMGD based on scoring
models.
Kebebew et al. at San Francisco described a dichotomous
scoring model based on preoperative total calcium level
(≥3 mmol/L (≥12 mg/dL)), intact parathyroid hormone level
(≥2 times the upper limit of normal levels), positive ultrasound
and sestamibi scan results for one enlarged gland, and concor-
dant ultrasound and sestamibi scan findings. The model was
derived from data collected on 238 patients, of whom 75.2 %
had a single adenoma, 21.4 % had asymmetric four-gland
hyperplasia and 3.4 % had double adenomas [23]. The posi-
tive predictive value of this scoring model to correctly predict
single-gland disease was 100 % for a total score of three or
higher. The authors suggested that patients with a score of
three or higher can undergo a minimally invasive parathyroid-
ectomy without the routine use of intraoperative parathyroid
hormone or additional imaging studies, and those with a score
of less than 3 should have additional testing to ensure that
multiglandular disease is not overlooked [62]. The usefulness
of the Kebebew scoring model was validated by Elarai et al. at
the same institution in a twofold larger cohort of patients (n=
487) [64], and independently by Kavanagh et al. in a cohort of
180 patients treated in Ireland [65].
Preoperative oral calcium-loading test was proposed as an
adjunct in the differential diagnosis between adenoma and
hyperplasia. After oral administration of 1 g of calcium
gluconolactate, 32 patients and 32 controls had calcium and
PTH measured before and at 60, 120 and 180 min afterwards.
PTH decline <30 %, product P (minimal PTH concentration
(pg/mL)×maximal calcium concentration (mg/dL))>1100,
and ratio R (relative PTH decline/relative calcium increase)<
4 diagnosed adenoma with specificity of 100, 90 and 100 %,
respectively. PTH decline >60 % diagnosed hyperplasia with
specificity of 100 %. The total accuracy of the test was 65 %
[66]. This model has not been confirmed by other groups.
Chen et al. at Wiscosin University proposed the Wisconsin
Index (WIN), defined as the multiplication of preoperative
serum calcium by preoperative PTH. Patients were divided
into three WIN categories: low (<800), medium (801–1600)
and high (>1600). Data from 1235 patients was used to derive
a WIN nomogram, consisting of the combination of WIN and
parathyroid gland weight. This nomogram accurately predict-
ed the likelihood of additional hyperfunctioning parathyroid
glands. For example, for a WIN of less than 800 and a gland
weight of 500 mg, there is a 9 % chance for additional hyper-
functioning parathyroid glands based on the WIN nomogram.
In contrast, for the same gland weight, if the WIN is 801 to
1600, these chances increase to 28 %, and if the WIN is more
than 1600, the chance of multiglandular disease is 61 %. This
simple intraoperative tool may be used to guide the decision of
whether to wait for intraoperative PTH assay (IOPTH) results
or to proceed with further neck exploration [13].
Most recent development was proposed by Udelsman et al.
from Yale University [67]. A mathematical model for pHPT
was developed and embedded in a software to yield intraop-
erative predictability curves. A cohort of 617 patients (554
single adenoma (SA) and 63 MGD) was used to generate an
idealised model that was embedded in software and installed
in a laptop computer to enable intraoperative decision analy-
ses, PTH curve plotting, and storage and transmission of data.
A subsequent cohort of 100 consecutive unselected patients
(81 single adenomas and 19 MGD including 13 cases of
hyperplasia, two MEN-1, one lithium, three double
adenomas) were tested using this model. The model predicted
an overall curative resection in 95 % of patients. In single
adenoma patients, cure was predicted in 78/81 patients with
a mean probability of 99.3 % at 11.8±10.4 min postresection.
The model also correctly predicted residual hyperfunctioning
tissue in all tested multiglandular patients. All MGD patients
underwent additional exploration with resection of residual
disease resulting in a mean predicted cure rate of 97.9 % at
10.6±7.3 min postresection completion in 17 patients. This
intraoperative prediction software expedites termination of
surgery with a high level of curative confidence. Alternatively,
the model accurately predicts residual disease prompting ad-
ditional exploration. Because the model is based on a large set
of multivariate regression curves, PTH values obtained at any
postresection sampling interval generate prediction data with
far greater accuracy than existing algorithms. The software is
designed for convenient operative use and can print, store and
electronically transmit probability analyses and PTH curves in
real-time [67].
Can sestamibi distinguish single-gland from sporadic
multiglandular disease?
Sestamibi scan has a high sensitivity to localise a solitary
parathyroid adenoma in patients even with mild increase in
serum calcium level [68]. The sensitivity decreases signifi-
cantly in patients with MGD and concomitant thyroid nodular
abnormalities [69]. In one study, sestamibi subtraction scintig-
raphy correctly localised 31/36 (86 %) parathyroid adenomas
compared with only 17/36 (47 %) by thallium subtraction
scintigraphy (p<0.001) [68]. There was one false-positive re-
sult in the sestamibi group because of a thyroid adenoma, and
two of the scans were negative. Both the sestamibi and the
thallium subtraction scintigraphy localised one single en-
larged gland in all three patients with multiple gland involve-
ment. In no case was MGD predicted.
In another study form Bergenfelz et al. [70] in the six pa-
tients with incorrect scans, two patients with solitary parathy-
roid adenoma were not correctly lateralized and four patients
had asymmetric hyperplasia with two enlarged glands each
[70]. Thus, in no patient was MGD predicted by the scan.
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The reason for this low sensitivity is not clear and wide
range of accuracy for sestamibi scintigraphy has been reported
in a meta-analysis [71]. The sensitivity of sestamibi scintigra-
phy has been associated with the size of the parathyroid ade-
noma, the level of serum calcium and PTH, as well as the
oxyfilic content of tumour, and concomitant thyroid disease
[72]. The data from Nichols et al. showed MIBI scintigraphy
to be significantly less sensitive (61 vs. 97%) and less specific
(84 vs. 93 %) for detecting MGD than single-gland disease
and that the sensitivity of the test decreases progressively as
the number of the lesion increased (Tables 3 and 4) [73, 74].
The possible factor in explaining the reduced MIBI sensitivity
and specificity for MGD could be: (a) weight of parathyroid
lesion: parathyroid lesions in multiple gland disease are smaller
than in singular gland disease; (b) histology:MGD is usually due
to hyperplasia whereas singular gland disease is due to adenoma
and MIBI imaging has been reported to be less sensitive for
detecting hyperplastic than adenomatous glands [74–77].
What is the risk of sporadic multiglandular disease
when a sestamibi scan is negative?
Most published reports regarding this issue are contempora-
neous or historical controls, retrospective studies, single insti-
tutional series or cohort studies with less than 50 cases. In
some reports, the small number of cases and events precluded
the application of statistical analysis. Some data that would be
informative, such as symptoms at presentation, medical histo-
ry, patient comorbidities, radiographic studies, intent of sur-
gery, operative reports, rates of recurrence and pertinent sero-
logic laboratory values, were not analysed because they were
not collected in the database.
There is only one large series with extensive data [72].
Results from the preoperative investigations with sestamibi
scintigraphy revealed: MGD was not predicted in 55/1474
patients (3.7 %); while there was a false prediction of MGD
in solitary adenoma in 6/1473 patients (0.4 %) and a correct
prediction of MGD in 10/1473 patients (0.7 %). Negative
examinations were 351/1473 (23.0 %) [72]. In comparison,
results from the preoperative investigations with ultrasound
revealed: correct position of one pathologic gland, but MGD
not predicted in 27/1120 patients (2.4 %); false prediction of
MGD in solitary adenoma in 7/1120 patients (0.6 %); and
correct prediction of MGD in 10/1120 Patients (0.9 %). Nega-
tive examinations were 348/1120 (31.0 %) [72]. Therefore, if
investigation with sestamibi scintigraphy and ultrasound is neg-
ative, surgery is probably more difficult than for patients with
no localization investigation, or with a positive localization test.
Negative localization with sestamibi and ultrasound in
pHPT infers a highly selected patient population with small
parathyroid adenomas, an alarmingly high rate of negative
exploration and an increased risk for persistent disease with
Table 3 Scintigraphy is
significantly less sensitive and
less specific for detecting MGD
than singular gland disease
Prelesion test characteristics for all patients
MGD lesions SGD lesions All lesion
Sensitivity 61 %* (201/331) 97 % (503/520) 83 % (704/851)
Specificity 84 %* (163/193) 93 % (1450/1560) 92 % (1613/1753)
Accuracy 69 %* (364/524) 94 % (1953/2080) 89 % (2317/2604)
Positive predictive value 87 % (201/231) 82 % (505/613) 83 % (704/844)
Negative predictive value 56 %* (163/293) 99 % (1450/1467) 92 % (1613/1760)
Modified form refs. [73, 74]
MGD multiglandular disease, SGD single gland disease
*p<0.05 MGD vs. SGD
Table 4 The sensitivity of the
test decreases progressively as the
number of the lesion increases
Effect of increasing lesion number per patient on test performance
1 lesion 2 lesions 3 lesions 4 lesions
Sensitivity 97 % (503/520) 68 %* (100/148) 59 %* (79/135) 46 %* (22/48)
Specificity 93 % (1450/1560) 84 %* (124/148) 87 %* (39/45)
Accuracy 94 % (1953/2080) 76 %* (224/296) 66 %* (118/180) 46 %* (22/48)
Positive predictive value 82 % (505/613) 81 % (100/124) 93 %* (79/85) 100 % (22/22)
Negative predictive value 99 % (1450/1467) 72 %* (124/172) 41 %* (39/95) 0 %* (0/26)
Modified form refs. [73, 74]
*p<0,05 vs. one lesion
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outcome inferior than standards. This was confirmed in a
study of 213 patients operated for pHPT after dual scanning
with sestamibi and US [62]. When at least one study showed a
positive result (n=175), the patient underwent a video-assisted
approach with IOPTH monitoring. When results were nega-
tive (n=38), the patient underwent cervicotomy and explor-
atory procedures of all four parathyroid glands. All patients
were cured (mean follow-up, 17.8±10.3 months). Patients
with negative preoperative study results had a high risk of
MGD (12/38 patients; 31.6 %), compared with patients with
one positive study result (3/83 patients; 3.6 %; p<0.001) and
those with two concordant positive study results (0/92 pa-
tients; p<0.001). The authors concluded that when preopera-
tive localization study results are negative, the patient has a
high risk of MGD, and a conventional cervicotomy with iden-
tification of the four glands is recommended strongly. When
only one localization study is positive, the risk of MGD jus-
tifies the use of IOPTHmonitoring during a focused approach.
When positive localization study results are concordant, the
use of IOPTH is questionable during a focused approach [62].
How accurate is the use concordant sestamibi scan
and ultrasound for distinguishing single gland
from sporadic multiglandular disease?
Combined sestamibi and US can increase the accuracy of
localization of a single adenoma from 94 to 99 %. When
concordant, sestamibi and US localization has been reported
to have an operative success rate approaching 99 % [78–81].
Discordance between sestamibi and US has been reported to
be as high as 38 % in consecutive patients treated by parathy-
roidectomy, with an 11 % rate of MGD [82]. Although the
sensitivities for both localising studies for MGD are lower, the
risk of missing abnormal glands can be minimised by utilising
IOPTH monitoring [82].
What is the accuracy of CT scan for distinguishing
single-gland disease from sporadic multiglandular
disease?
CT is advised when an ectopic, mediastinal parathyroid lesion
is seen on sestamibi, in previous neck surgery and/or
coexisting thyroid disease [77, 83–85]. Most studies have in-
vestigated its ability to localise adenomas rather than to iden-
tify MGD.
More recently, 4D-CT scan has been described to be a very
sensitive technique [86]. The name is derived from 3D-CT
with an added dimension from the changes in perfusion of
contrast over time. 4D-CT utilises multiplanar images and
perfusion characteristics to identify abnormal parathyroid
glands [86]. By evaluating for an early enhancing and early
washout of parathyroid glands, individual enhancement char-
acteristic can then be correlated with metabolic activity, which
allows 4D-CT to demonstrate gland functionality in addition
to providing anatomic details.
Few studies assessed the role of 4D-CT in patients with
inconclusive preoperative ultrasound and sestamibi localiza-
tion studies. The study from Philip et al. demonstrated that
4D-CT scan had improved sensitivity (88 %) over sestamibi
imaging (65 %) and ultrasonography (57 %) in localising hy-
perfunctioning parathyroid glands [82]. Table 4 shows the
values of sensitivity and specificity that emerged from the
study of Rodgers et al. in which 11 of 75 patients had MGD.
4D-CT identified ≥2 glands in five of these patients (45 %).
This was in contrast to sestamibi, which identified ≥2 glands
in only one patient [77]. In the study of Lubitz et al., compris-
ing 60 patients, 4D-CT accurately lateralized 73 % and local-
ised 60 % of abnormal glands found at operation (Table 5).
Single candidate lesions (46/60) were confirmed at operation
in 70%.Whenmultiple lesions were identified on 4D-CT (14/
60), accuracy dropped to 29% (p=0.03). The accuracy of 4D-
CT was not different between primary and reoperative cases
(p=0.79). Of the eight patients with MGD diagnosed
perioperatively, five had multiple candidate lesions noted on
4D-CT. In 94 % (48/51) of patients, a >50 % drop in IOPTH
level was achieved after resection and 87 % (48/55) had long-
term cure with a median follow-up of 221 days. Authors con-
cluded that 4D-CT identifies more than half of abnormal para-
thyroids missed by traditional imaging and should be consid-
ered in cases with negative or discordant sestamibi and ultra-
sound [86]. Bilateral exploration is warranted when multiple
candidate lesions are reported on 4D-CT. However, taking
into consideration that 4D-CT carries a huge radiation expo-
sure, BNE remains the gold standard surgical approach having
a high success rate in experienced hands in cases with
Table 5 Values of sensitivity and specificity that emerged with 4D-CT
scan
Sensitivity and specificity of imaging for localization of parathyroid
tumours to side of the neck and quadrant of the neck
Variable Sensitivity
(95 %)
95 % CI Specificity
(%)
95 % CI
Side of the neck
4D-CT 88 81–95 88 80–96
Ultrasonography 57 47–67 94 88–99
Sestamibi 65 55–75 88 80–96
Precise location in the neck
4D-CT 70 59–81 89 85–93
Ultrasonography 29 20–38 86 82–90
Sestamibi 33 24–42 83 79–87
Modified from ref. [77]
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negative or discordant sestamibi and ultrasound (grade C rec-
ommendation, GRADE: high, ‘⊕⊕⊕⊕’).
How accurate is SPECT imaging for distinguishing single
gland from sporadic multiglandular disease?
SPECT/CT provides fused images of functional and anatom-
ical modalities which considerably improve the interpretation
of findings of individual procedures [87–89]. This innovation
might improve the relatively poor results obtained in the de-
tection of multiglandular hyperplastic disease, but further data
are needed to establish its role in the field. In 2009, Wimmer
et al. analysed the sensitivity and specificity of CT-MIBI-
SPECT in 30 patients [75]. The aim of this study was to
evaluate whether CT-MIBI-SPECT image fusion is superior
to MIBI-SPECT alone and CT alone in detecting abnormal
parathyroid tissue in patients withMGD (Table 6). There were
six patients with pHPT (4 MEN-1 syndromes and 2 double
adenomas; 1 of these patients had HRPT2 gene mutation), 14
with secondary, 8 with tertiary HPT and 1 patient each suffer-
ing from persistent primary and persistent secondary hyper-
parathyroidism. In five out of six patients with MGD,
more than one gland was detected, thus MGD could
be suspected preoperatively. Overall, CT-MIBI-SPECT
image fusion was able to predict the exact position of
all abnormal glands per patient in 14 of 30 (46.7 %)
cases, whereas CT alone was successful in 11 (36.7 %),
and MIBI-SPECT alone just in four (13.3 %) of 30
patients. This study demonstrated that CT-MIBI-SPECT
image fusion is superior to CT or MIBI-SPECT alone in
preoperative localization of all pathologic glands in pa-
tients suffering from MGD [75].
Is genetic testing justified in patients with seemingly
sporadic multiglandular disease under 40 years of age
to rule out hereditary parathyroid disease?
MEN-1 is an autosomal dominant disorder characterised by
the occurrence of tumours of the parathyroid, enteropancreatic
neuroendocrine tissues and anterior pituitary. It is a rare dis-
ease with an estimated prevalence of 0.01–2.5 cases per 1000
individuals [90]. The presentation ofMEN-1 occurs within the
context of previously identified kindred, in a newly
ascertained individual with advanced disease who might be
the proband of new kindred or as a de novo mutation. Com-
paring tumours in the same tissues, they usually appear one to
two decades earlier in the familiar forms compared with the
sporadic ones [91]. The MEN-1 gene was identified in 1997
and consists of 10 exons on chromosome 11q13 encoding a
610-amino acid protein known as Menin. More than 1300
mutations have been identified in the MEN-1 gene to date,
and there is no evidence of genotype-phenotype correlations
(as in MEN-2) [92, 93].
The prevalence of MEN-1 among patients with apparently
sporadic component tumours varies widely by tumour type.
Approximately 1/3 of patients with Zollinger-Ellison syn-
drome will carry a MEN-1 mutation [90]. In individuals with
apparently isolated hyperparathyroidism or pituitary adeno-
mas, the mutation prevalence is lower (2 % to 5 %), but the
prevalence is higher in individuals diagnosed with these tu-
mours at younger ages (<40 years old) [94–96]. Some authors
suggest MEM-1 testing in those not meeting diagnostic
criteria if one of the following is present: gastrinoma at any
age, multifocal pancreatic islet cell tumours at any age, para-
thyroid adenomas before age of 40 years, multiglandular para-
thyroid adenomas or recurrent hyperparathyroidism or
Table 6 Accuracy of SPECT imaging for distinguishing single gland from sporadic MGD
SGD vs. MGD
Statistic and disease Early images Late images Subtract on
images
SPECT
images
Early and late
images
Planar images All images
Sensitivity (%)
SGD 74 (303/400)* 87 (355/409)* 88 (360/409)* 90 (369/409)* 90 (370/409)* 96 (392/409)* 90 (369/409)*
MGD 63 (79/125) 65 (81/125) 54 (68/125) 59 (74/125) 61 (76/125) 63 (79/125) 66 (82/125)
Specificity (%)
SGD 93 (433/464) 92 (427/464) 94 (435/464) 84 (390/464) 90 (419/464) 89 (410/464) 98 (453/464)*
MGD 82 (9/11) 82 (9/11) 73 (8/11) 82 (9/11) 82 (9/11) 64 (7/11) 73 (8/11)
Accuracy (%)
SGD 84 (736/873)* 90 (782/873)* 91 (795/873)* 87 (759/873)* 90 (789/873)* 92 (802/873)* 94 (822/873)
MGD 65 (88/136) 66 (90/136) 56 (76/136) 61 (83/136) 63 (85/136) 63 (86/136) 66 (90/136)
Modified form ref. [75]
MGD multiglandular disease, SGD single gland disease
*p<0.05 for comparison with data for MGD
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individuals with one of the three main MEN-1 plus one of the
less common findings [92, 96]. Balogh K et al. summarised
the indications for genetic screening for MEN-1 (Table 7)
[76]. The methods of screening are outside the remit of this
paper.
Surgical treatment of sporadic multiglandular
disease
Bilateral neck exploration for sporadic multiglandular
disease
Although most patients with pHPT are ideal candidates for
MIP, somewill havemore than one enlarged gland and require
BNE to achieve biochemical cure. Interestingly, the evidence
is unclear as to whether all enlarged parathyroid glands are
hyperfunctioning, because no prospective study has been
done without removing such glands to determine if patients
are at risk for persistent or recurrent disease [3].
In a systematic review including 2166 patients from 14
studies who underwent BNE, 79.7 % had a single adenoma
and 19.3 % had multiglandular disease. Of 2095 patients in 31
studies with a focal unilateral approach, 92.5 % had a single
adenoma, whereas only 5.3 % had MGD. Thus, the incidence
ofMGDwas significantly lower among patients treated with a
focal unilateral approach compared with a bilateral approach
(p<0.001). Hence, it was postulated that a focal unilateral
surgical approach for pHPT might underestimate the inci-
dence ofMGD [97]. Actually, more recent data do not confirm
an increased prevalence of recurrent hyperparathyroidism
among patients initially treated by focal approach. Schneider
et al. analysed retrospectively 1368 parathyroid operations for
pHPT including 1006 MIPs and 380 BNEs. There were no
differences in recurrence between MIP and BNE groups (2.5
vs. 2.1 %; p=0.68), and the operative approach did not
independently predict recurrent disease in the multivariable
analysis [98]. Hence, it should be taken into consideration that
some grossly enlarged and histologically abnormal parathy-
roid glands can be non-functional and BNE may lead to over-
treatment at least in some patients with pHPT.
There is no level I or II evidence to answer the question of
which patients with pHPT should undergo BNE. However, it
should be considered in MEN-1 syndrome, negative preoper-
ative localization studies and inadequate decrease of IOPTH
level following removal of the image-indexed parathyroid le-
sion. All other clinical scenarios can be regarded as relative
indications for BNE and include isolated familial PHPT,
MEN-2 syndrome, history of lithium therapy, history of head
and neck irradiation or discordant preoperative localization
studies (grade C recommendation, GRADE: moderate,
⊕⊕⊕O).
Is there a place for minimally invasive surgery
in lithium-associated hyperparathyroidism?
The overall incidence of MGD calculated from several recent
series of LAH was 51 %, ranging from 4/16 (25 %) [99], 6/19
(32 %) [100], 36/71 (52 %) [34], 27/48 (56 %) [101] and 16/
27 (62 %) [102] (Table 8). For this reason, many advocate
BNE for all such patients, although the use of IOPTH might
allow for a more limited exploration in selected patients who
demonstrate an appropriate intraoperative fall in PTH.
In a large cohort of 1207 consecutive patients, the rate of
MGD was not higher in LAH: present in 25 % (4/16) patients
with LAH and 12.3 % (146/1191) patients without LAH (p=
0.13). Among 16 patients with LAH, 12 (75 %) had a single
adenoma. The use of IOPTH allowed unilateral exploration in
8 of 12 patients with single adenoma. Parathyroid exploration
resulted in durable biochemical cure for all 16 patients with
LAH. Authors concluded that MGD seems to be no more
frequent in patients with LAH than in patients with pHPT
Table 7 Summary of the indications for genetic screening
Clinical manifestation of MEN-1 syndrome and indications for genetic screening
Major lesion (prevalence) Minor lesions Indications for genetic screening
Hyperparathyroidism (90–97 %) Adrenal adenomas Index case
Pituitary adenoma (33 %) Facials angiofibromas Clinically defined MEN-1
Tumours of endocrine pancreas (30–80 %) Lipomas (2 major lesions; 3 major and minor lesions)
Neuroendocrine carcinoids Clinically suspicious or atypical MEN-1
Thyroid neoplasms
Phaeochromocytomas
Malignant melanomas Member of a MEN-1 family
Testicular teratomas All first degree relatives: a relative who shows
signs or symptoms of MEN-1
Modified from ref. [76]
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without LAH, and patients with LAH can be safely and effec-
tively managed with selective unilateral exploration directed
by intraoperative IOPTH [99].
However, the eligibility of LAH patients for unilateral neck
exploration is still a matter of debate. Marti et al. presented
retrospective analysis of 27 patients with LAH undergoing
parathyroidectomy with the IOPTH. Cervical exploration
was unilateral in 9, bilateral in 18 (three were converted from
unilateral). Twenty-five (92.6 %) of 27 patients had initially
successful surgery. Of the 17 patients with >6 months follow-
up, two had persistent disease (11.8 %) and two (11.8 %)
experienced recurrent disease. All patients with a single ade-
noma remain free of disease. Three (75 %) of four patients
with persistent/recurrent disease had multiglandular disease
and were receiving lithium at the time of surgery. Patients with
persistent/recurrent disease were older (p=0.01) and had ex-
perienced a longer duration of hypercalcemia (p=0.04). Based
on their outcomes authors concluded that LAH patients have a
high incidence ofMGD, and bilateral exploration is frequently
necessary. With access to the IOPTH, it is reasonable to initi-
ate a unilateral approach because many patients will harbour
single adenomas and can be reliably rendered normocalcemic.
Patients with MGD remain at higher risk of persistent/
recurrent disease [102].
Wade et al. performed a retrospective review of a prospec-
tive, single institution parathyroid database of 1010 patients
who underwent parathyroidectomy between December 1999
and October 2010. Nineteen (1.9 %) patients with a history of
lithium therapy and sporadic pHPTwere identified. A total of
18 patients underwent preoperative imaging. Of 12 (67 %)
patients with single-site localization, 6 (50 %) underwent a
minimally invasive parathyroidectomy, 2 (17 %) underwent
unilateral explorations, 1 (8 %) underwent bilateral explora-
tion and 3 (25 %) had concomitant thyroidectomies. Six pa-
tients did not localise and underwent bilateral exploration for
multiglandular disease. One patient without preoperative im-
aging had single-gland disease. In all operations, surgeons
used IOPTH and met intraoperative criteria. Median IOPTH
decrease was 74 % (54–86) in single-gland disease and 85 %
(76–95) inMGD.Median abnormal gland weight was 590 mg
(134–6750 mg) in single-gland disease and 296 mg (145–
2170 mg) in MGD. All patients were normocalcemic at a
median follow-up of 19 months (2–118). Authors concluded
that of 19 patients with lithium exposure, 6 (32 %) had MGD.
However, of the 13 (68 %) patients with a single-gland dis-
ease, all 12 who had preoperative imaging had single-site
localization. Thus, if localization suggests single-gland dis-
ease, minimal invasive parathyroidectomy with IOPTH can
be successfully performed [100].
More limited confidence inMIP for LAHwas presented by
Skandarajach et al. who reviewed their multi-institutional ex-
perience based on surgical treatment of 15 patients with LAH.
All 15 patients had preoperative imaging: sestamibi scanning
showed that 10 (67 %) patients had localised single-gland
disease, 1 (7 %) had multiple hot spots and 4 (27 %) had a
negative scan. Ultrasonography demonstrated a single abnor-
mal gland in 8 (50 %) patients and multiple enlarged glands in
1 (7 %) patient; the test was negative in 6 (40 %). As a con-
sequence of concordant preoperative imaging a minimally in-
vasive approach (endoscopic or a focused lateral approach)
was adopted in 3 (20 %) patients. Focused surgery demon-
strated an enlarged hyperplastic gland in all three cases and
resulted in normocalcemia in the immediate postoperative pe-
riod. None of these patients showed evidence of recurrence at
follow-up. Thus, LAH is predominantly a MGD characterised
by asymmetrical hyperplasia that is frequently associated with
misleading or discordant localization studies. BNE is there-
fore recommended in order to minimise the risk of disease
recurrence [101].
Järhult et al. analyzed retrospectively the long-term out-
come after surgery for LAH in a large series of patients.
Seventy-one patients on chronic lithium therapy who
underwent surgery in three university and three district hospi-
tals in Sweden were followed for a median of 6.3 years. The
primary histopathological diagnoses were adenoma (45 %),
double adenomas (3 %) and hyperplasia (52 %). Thirteen
per cent of the patients suffered from permanent hypoparathy-
roidism. At follow-up, the rate of persistent and recurrent HPT
Table 8 Surgical management of LAH based on recent publications
Reference (year) No of patients
with LAH
IOPTH Pathology (%) Surgery (%) p/rHPT (%) Perm. HypoPT
(%)
SA DA PH BNE Scan-directed
Wade et al. [100] 19 Yes 68 32 (MGD) 53 47 100 0
Marti et al. [102] 27 Yes 41 15 44 67 33 23 0
Skandarajah et al. [101] 15 Yes 27 0 73 80 20 0 7
Järhult et al. [34] 71 N/A 45 3 52 97 3 42 13
Carchman et al. [99] 16 Yes 75 12.5 12.5 50 50 0 0
LAH lithium-associated hyperparathyroidism, SA single adenoma,DA double adenoma, PH parathyroid hyperplasia,MGDmultiglandular disease, BNE
bilateral neck exploration, p/rHPT permanent/recurrent hyperparathyroidism, Perm.HypoPT permanent hypoparathyroidism
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was 42 % regardless of the histopathological diagnosis. The
authors concluded that the results of conventional surgery for
LAH are poor. The surgical approach should be adjusted for
the MGD that is usually the cause of HPT in patients on
chronic lithium therapy [34].
Thus, there is conflicting and equally weighted low level
evidence supporting a routine preoperative plan of bilateral
neck exploration vs. selective unilateral exploration for LHA
(no recommendation) [3].
Is IOPTH monitoring helpful for the detection
and postoperative outcome prediction in sporadic
multiglandular disease?
The IOPTH assay is widely utilised to confirm complete re-
moval of all hyperfunctioning parathyroid tissue, which al-
lows for termination of surgery with confidence that the
hyperparathyroid state has been successfully corrected and
to identify patients with additional hyperfunctioning parathy-
roid tissue following the incomplete removal of diseased para-
thyroid/s, hence minimising the risk of operative failure.
Understanding the nuances of IOPTH monitoring allows
surgeons to achieve intraoperative confidence in predicting
operative success and preventing failure in cases of unsuspect-
ed MGD, while safely limiting neck exploration in the major-
ity of patients with sporadic pHPT. When concordant results
of functional imaging (e.g. sestamibi scanning) and ultrasound
performed by an experienced investigator are obtained, MIP
can be safely recommended [103, 104]. The prevalence of
MGD among patients with pHPT and concordant imaging
tests varies from 1 to 3.5 % [104, 105]. Thus, when preoper-
ative localization with sestamibi and ultrasound is concordant
for single-gland disease, the use of IOPTH monitoring is of
little value. However, if preoperative localization with
sestamibi and ultrasound is not concordant and the surgeon
wishes to perform a minimally invasive ‘selective’ operation,
the use of IOPTH monitoring is recommended, as the preva-
lence of MGD in this subgroup of patients with pHPT ap-
proaches 17 % [109–112]. Similarly, the use of IOPTH mon-
itoring is recommended for patients undergoing selective
parathyroidectomy on the basis of a single preoperative local-
ization study [106].
On the other hand, the accuracy of IOPTH monitoring in
the detection of patients withMGD is highly dependent on the
criteria applied. A retrospective validation of different IOPTH
criteria have shown that the Miami criterion followed by the
Vienna criterion is the best balanced among other criteria, with
the highest accuracy in intraoperative prediction of cure [104].
However, the Rome criterion followed by the Halle criterion is
most useful in intraoperative detection of multiglandular dis-
ease [104, 107–109] (Table 9). Nevertheless, their applica-
tion in patients qualified for minimally invasive parathy-
roidectomy with concordant results of sestamibi scan-
ning and ultrasound of the neck would result in a sig-
nificantly higher number of negative conversions to bi-
lateral neck explorations and only a marginal improve-
ment in the success rate of primary operations [104].
Thus, the accuracy of IOPTH monitoring is highly de-
pendent on the criteria used by the surgeon to predict
the outcome of parathyroid surgery. In addition,
Carneiro-Pla et al. underlined that histopathology of ex-
cised abnormal parathyroid glands did not predict the
secretory function of the remaining parathyroid glands
left in situ. IOPTH guided parathyroidectomy accurately
based on function alone; however, histopathology was
inaccurate in predicting MGD and should not be used
to guide parathyroidectomy in patients with sporadic
pHPT [107].
Nevertheless, controversy remains over the utility of
IOPTH in MGD, with concern for false-positive results lead-
ing to prematurely concluding the operation and leaving be-
hind abnormal parathyroid tissue, risking future recurrence.
Cayo et al. analysed group of 755 patients who underwent
parathyroidectomy and 163 (21.5 %) were found to have
MGD on pathology. IOPTH monitoring was used in 161 of
these cases. In 146/161 cases (90.7 %), the IOPTH level fell
by at least 50 % after removal of all suspected abnormal
glands. All of these patients (100%) remained normocalcemic
postoperatively. In 15/161 cases (9.3 %), the PTH level did
not fall by >50 %. For 11/15 cases (73 %), patients remained
hypercalcemic postoperatively or had recurrence. However, in
the remaining four cases, the patients became normocalcemic
postoperatively despite failure of the PTH to fall by >50 %. In
each of these patients, PTH levels fell by 40–50 %. Thus,
IOPTH monitoring accurately predicted success or failure of
Table 9 IOPTH predictive values when using different criteria
Reference (year) MGD/SA (%) Criterion PPV (%) NPV (%) Conclusion
Barczynski et al. [104] 9/260 (3.5) Halle 100 14.2 Miami criterion followed by the Vienna criterion is the best balanced among
other criteria, with the highest accuracy in intraoperative prediction of cure.
However, the Rome criterion followed by the Halle criterion is most useful
in intraoperative detection of MGD.
Miami 99.6 70
Rome 100 26.3
Vienna 99.6 60.9
MGD multiglandular disease, SA single adenoma, PPV positive predictive value, NPV negative predictive value
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parathyroidectomy in 97.5 % (157/161) of patients with
MGD. A fall of IOPTH by >50 % can be used as a highly
accurate predictor of cure in patients with MGD [16].
McCoy et al. analysed initial parathyroid operations of
1150 patients treated in 1998–2012 and found that 15 % had
MGD.MGD risk varied inversely with weight of first resected
abnormal gland. Microadenoma required BNE more often
than macroadenoma (48 vs. 18 %; p<0.01). When at explo-
ration the first resected gland was <200 mg, the rates of MGD
(40 vs. 11 %; p=0.001), inadequate initial IOPTH drop (67 vs.
79 %; p=0.002), operative failure (6.6 vs. 0.7 %; p<0.001),
and long-term recurrence (1.6 vs. 0.3 %; p=0.007) were
higher. Thus, during exploration for sporadic pHPT, a first
abnormal gland <200 mg should heighten suspicion of
MGD and presages a tenfold higher failure rate [110].
The European Society of Endocrine Surgeons (ESES) rec-
ommended the use of IOPTH monitoring for patients under-
going ‘targeted’ parathyroidectomy on the basis of a single
preoperative localization study. If preoperative localization
with sestamibi and ultrasound is not concordant and the sur-
geon wishes to perform a minimally invasive ‘targeted proce-
dure’, the use of intraoperative IOPTH monitoring is recom-
mended. When preoperative localization with sestamibi and
ultrasound is concordant for single-gland disease, the use of
this adjunct is of little value. In addition, the use of IOPTH can
be recommended in reoperative parathyroidectomy to lateral-
ize hyperfunctioning parathyroid tissue (internal jugular vein/s
sampling) when preoperative localization is uncertain or to
predict cure and reduce the need for continued exploration
in the scarred neck [103, 106].
Is local anaesthesia with intravenous sedation feasible
surgical treatment of sporadic MGD?
There are no reported cohorts addressing this issue.
Long-term results of surgical treatment for sporadic
multiglandular disease
Does cure rate of surgery for sporadic MGD differ
from outcomes of surgery for solitary parathyroid
adenoma?/prevalence of persistent sporadic MGD
An accurate cure rate is impossible to calculate as one does not
know exactly the value of the denominator (i.e. the exact
number of patients with MGD in a population) and most esti-
mates are based on how common is MGD demonstrated in
patients with persistent pHPT after resection of a single
adenoma.
Because patients with MGD are not expected to have con-
cordant localization studies, they are more likely to be identi-
fied in the subgroup of patients with negative or non-
concordant scans. For example, in a group of 492 patients,
those with positive sestamibi scan results compared with those
with negative results had a higher rate of single-gland disease
(87 vs. 63%, respectively) and lower rates of double adenoma
(6 vs. 22 %, respectively) and asymmetric hyperplasia (7 vs.
15 %, respectively) (p<0.001) [111]. Similarly, the incidence
of MGD in a large series of 2185 patients was at least twice
higher (12.8 vs. 5.4 %) in the subgroup of 836 (38 %) of
patients with non-localising scans when compared with those
with positive scans. The authors reported no difference in
intraoperative success (93.9 vs. 95.6 %) or cure rates (96.2
vs. 97.7 %) between non-localised and localised groups [112].
Excellent cure rates were reported fromWisconsin Univer-
sity in a group of 161 patients with MGD identified within a
cohort of 755 patients. In 146/161 cases (90.7 %), the IOPTH
level fell by at least 50 % after removal of all suspected ab-
normal glands and all of these patients (100 %) remained
normocalcemic postoperatively. In 15/161 cases (9.3 %), the
PTH level did not fall by >50 % and 11 of these 15 patients
remained hypercalcemic postoperatively or had recurrence.
However, in the remaining four cases, the patients became
normocalcemic postoperatively despite failure of the PTH to
fall by >50 % [16].
Others have also reported that the failure to decrease
IOPTH by >50 % and into normal range is more common in
MGD than in patients with single adenomas (35.2 vs. 16.6 %)
[113] and that a modified criteria of a drop in IOPTH of >75%
from baseline and within normal range should be used to
predict adequate gland resection when MGD is identified dur-
ing focused parathyroidectomy [15]. In their experience, the
cure rate of MGD was less satisfactory as 14 of 193 (7.3 %)
patients with pHPT had persistent disease [15].
The general trend is that large series report cure rates sim-
ilar for MGD and for single adenomas. In a retrospective
analysis of 1402 patients, the rate of persistent pHPT was
higher among patients with double adenoma (4 %) vs. single
adenoma (1.3 %) and hyperplasia (2.2 %; p=0.0049) [10].
Wharry et al. analyzed 1108 initial parathyroid operations
for sporadic primary hyperparathyroidism using IOPTH and
reported that a long-term recurrence was more likely in pa-
tients with a final IOPTH level of 41–65 pg/mL than with a
level ≤40 pg/mL (1.2 vs. 0 %; p=0.016). Hence, patients with
a final intraoperative iPTH level between 41 and 65 pg/mL
should be followed up beyond 6 months for long-term recur-
rence [114].
The cure rate after excision ofMGD could be influenced by
the size of the remnant gland. This issue was addressed in a
study of 172 patients who underwent subtotal parathyroidec-
tomy (sPTX) for pHPTand were left with either a whole gland
remnant (WGR; n=108, 63 %) or a partial gland remnant
(PGR; n=64, 37 %) after sPTX. Cases with positive family
history for pHPT were more likely to have a PGR (12.5 vs.
3.7 %; p=0.03). Individuals with a PGR tended to have larger
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glands encountered by surgeons intraoperatively (525±1308
vs. 280±341 mg; p=0.02). Overall, the cure rate was 97 %
and recurrence rate of 5% after amean follow-up of 29months
[115].
Prevalence of recurrent sporadic multiglandular disease
In a retrospective analysis of 1402 patients, the recurrence rate
after a median follow-up time of 12months was higher among
patients with double adenomas (7.3 %) and MGD (4.4 %) vs.
single adenomas (1.7 %; p=0.0005). These data suggest that
double adenoma in some cases could represent asymmetric or
asynchronous hyperplasia. Hence, in situations where a dou-
ble adenoma has been identified, the surgeon should have a
high index of suspicion during surgery and postoperatively for
the possibility of four-gland disease (grade C recommenda-
tion, GRADE: moderate, ⊕⊕⊕O) [11].
Is more intense follow-up justified in sporadic
multiglandular disease?
There is no data reported on this topic. A consensus statement
should be issued based on ‘expert advice’.
Redo operations in sporadic multiglandular disease
There are no reported cohorts addressing this issue.
Summary
In the vast majority of patients with pHPTa single adenoma is
the cause of disease. In literature, the percentage of sporadic
MGD varies between 7 and 33 %. Of these, the majority is a
hyperplasia involving all parathyroid glands whereas the re-
maining is double, or in very rare cases, triple adenomas.
Histopathology can (with a fair degree of accuracy) distin-
guish between a normal and pathological parathyroid gland,
but be of limited aid to separate hyperplasia from adenoma.
There are, however, some histopathological findings
supporting parathyroid adenoma, fibrous capsule, solitary
nodule, nuclear pleomorphism, normal rim, fewer fat cells
and low/none intracellular fat. Hyperplasia on the other hand
is supported by more than one gland (usually all four, but not
mandatory) and involved nodule expansions of both chief and
oxyphilic cells, no clear capsule, fewer fat cells, and absence
of normal rim. However, needless to mention, there are sig-
nificant overlap in pathological characteristics between ade-
noma and hyperplasia, and there are no convincing and useful
histopathological criteria to differentiate between the two en-
tities. At present and in the near future, the best clinical prac-
tice is likely a close cooperation between the pathologist and
the surgeon. However, molecular biological methods may be a
useful instrument in the future to distinguish and discriminate
adenomas from hyperplasia.
Several issues demanded a comparison of published stud-
ies from different medical reports regarding preoperative di-
agnosis of sporadic MGD. As a consequence, it is difficult to
make valuable statements on preoperative diagnosis of spo-
radic MGD with a sufficient recommendation rating. There is
low evidence and recommendation from the literature for lo-
calization procedures for MGD.
Several limitation of the literature published to date have
emerged from this review.
The results of localization procedures were not always
compared with the results of neck exploration, definitive his-
tology and postoperative calcium status at the first follow-up
after discharge and were graded as follows: true preoperative
localization of solitary adenoma (TP); false preoperative lo-
calization of solitary adenoma (FP); correct position of one
pathological gland but MGD not predicted; false prediction
of MGD in solitary adenoma; correct prediction of MGD; and
lastly, negative/inconclusive preoperative examination [100].
Such a definition was not commonly applied to all
investigations.
Only a small number of randomised trials comprising a
comparatively modest number of patients have been pub-
lished from specialised centres on localization procedures. A
small number of studies analysed extensively preoperative
diagnosis of sporadicMDG [100].Moreover, localization pro-
cedures are not performed in all surgical procedures. In the
survey by Bergenfelz et al., localization procedures were per-
formed in 1831 of 2708 consecutively registered patients
(68 %) sestamibi scintigraphy in 1473 patients (54 %), ultra-
sound in 1120 patients (41%), CT in 62 patients (2%),MRI in
eight patients (0.3 %), venous sampling in 32 patients (1 %),
and PET in 34 patients (1%) [72].Moreover, only in two trials
(comprising 139 individuals), included patients that were not
selected on the basis of the results of the preoperative locali-
zation procedures [70, 116].
Finally, the cost effectiveness for diagnostic proce-
dures is debated for MGD. The argument regarding cost
effectiveness is important but difficult to analyse given
the variety in health care systems worldwide: waiting
lists, costs for re-operation, sick leave, localization ex-
aminations, IOPTH etc. [103].
There is no level I or II evidence to inform which patients
with pHPT should undergo BNE. Nevertheless, the presence
of certain clinical risk factors for MGD should be taken into
consideration in decision making which operative approach
should be used for individual patient. BNE should be consid-
ered in MEN-1 syndrome, negative preoperative localization
studies and inadequate decrease of IOPTH level following
removal of the image-indexed parathyroid lesion. All other
clinical scenarios can be regarded as relative indications for
BNE and include isolated familial PHPT, MEN-2 syndrome,
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history of lithium therapy, head and neck irradiation in anam-
nesis or discordant preoperative localization studies [117–120].
There is conflicting and equally weighted low level evi-
dence supporting a routine preoperative plan of bilateral neck
exploration vs. selective unilateral exploration for LHA (no
recommendation). The IOPTH assay can be utilised to con-
firm complete removal of all hyperfunctioning parathyroid
tissue, which allows for termination of surgery with confi-
dence that the hyperparathyroid state has been successfully
corrected and to identify patients with additional hyperfunc-
tioning parathyroid tissue following the incomplete removal
of diseased parathyroid/s, which necessitates extended neck
exploration in order to minimise the risk of operative failure.
To achieve a high success rate of parathyroidectomy, the sur-
geon needs to be aware of intraoperative hormone dynamics
during the case and carefully choose the protocol and inter-
pretation criteria that best fit the individual practice. Under-
standing the nuances of IOPTHmonitoring allows the surgeon
for achieving intraoperative confidence in predicting operative
success and preventing failure in cases of unsuspected MGD,
while safely limiting neck exploration in the majority of pa-
tients with sporadic pHPT.
Conflicting data exist in the literature regarding the preva-
lence of persistent and recurrent disease following parathy-
roidectomy for sporadic MGD vs. single-gland disease. The
general trend is that large series report cure rates similar for
MGD and for single adenomas. However, some data suggest
that double adenoma in some cases could represent asymmet-
ric or asynchronous hyperplasia. Therefore, in situations
where a double adenoma has been identified, the surgeon
should have a high index of suspicion during surgery and
postoperatively for the possibility of four-gland disease.
Recommendations
& Level V evidence supports that most single adenomas are
monoclonal lesions arising from a single precursor, where-
as sporadicMGD is polyclonal, hence a single parathyroid
adenoma and MGD represent two different diseases.
& Levels IV and V evidence supports that the majority of
cases with double parathyroid adenomas are synchronous.
This notion is based on the observation that few patients
have a recu r r en t d i s e a se a f t e r a succes s fu l
parathyroidectomy.
& Levels III to Vevidence supports an etiologic link between
sustained lithium therapy and both hypercalcemia and in-
creased PTH serum level.
& Levels IV and V evidence do not support any differences
with respect to gender, age and preoperative serum calci-
um and PTH levels between a solitary adenoma and spo-
radic MGD.
& Level V evidence do not support any differences in prev-
alence of a solitary parathyroid adenoma and sporadic
MGD among patients with radiation-induced vs. non-
radiation-associated pHPT.
& Levels III to V evidence supports that negative preopera-
tive localization studies in pHPTare highly predictive of a
small-sized solitary adenoma or MGD.
& Levels I to IV evidence supports that sestamibi scanning
and US have an unsatisfactory accuracy in predicting spo-
radic MGD, which is significantly inferior to a solitary
parathyroid adenoma.
& Level V evidence supports that 4D-CT identifies more
than a half of abnormal parathyroids in MGD missed by
traditional imaging. However, taking into consideration
that 4D-CT carries a huge radiation exposure, BNE re-
mains the gold standard surgical approach having a high
success rate in experienced hands in cases with negative or
discordant sestamibi and ultrasound (grade C recommen-
dation, GRADE: high, ‘⊕⊕⊕⊕’).
& Level V evidence supports that CT-MIBI-SPECT image
fusion is superior to CT or MIBI-SPECT alone in preop-
erative localization of all pathologic glands in patients
suffering fromMGD (grade C recommendation, GRADE:
high, ‘⊕⊕⊕⊕’).
& Levels III and IV evidence supports that genetic testing
should be undertaken in patients with seemingly sporadic
MGD under 40 years of age to rule out hereditary para-
thyroid disease (grade C recommendation, GRADE: high,
‘⊕⊕⊕⊕’).
& Levels III to V evidence supports that the presence
of certain clinical risk factors for MGD should be
taken into consideration in decision making which
operative approach should be used for individual pa-
tient. Hence, BNE should beconsidered in MEN-1
syndrome, negative preoperative localization studies,
and inadequate decrease of IOPTH level following
removal of the image-indexed parathyroid lesion.
All other clinical scenarios can be regarded as rela-
tive indications for BNE and include isolated famil-
ial PHPT, MEN-2 syndrome, history of lithium ther-
apy, head and neck irradiation in anamnesis or dis-
cordant preoperative localization studies (grade C
recommendation, GRADE: moderate, ⊕⊕⊕O).
& Levels IVand Vevidence supports the use of preoperative
parathyroid imaging if a unilateral/focused exploration is
planned in case of suspicion of sporadic MGD (grade C
recommendation, GRADE: moderate, ⊕⊕⊕O).
& Levels IV and V evidence supports the use of IOPTH
monitoring to guide appropriate surgical therapy in spo-
radic MGD (grade C recommendation, GRADE: moder-
ate, ⊕⊕⊕O).
& There is conflicting and equally weighted level Vevidence
supporting a routine preoperative plan of BNE vs.
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unilateral neck exploration for selected patients with
MGD, e.g. LAH (no recommendation).
& There is conflicting or equally weighted levels IV to V
evidence supporting that cure rates can be similar or worse
for sporadic MGD than for single adenomas. Best out-
comes can be expected if surgery is performed by an ex-
perienced parathyroid surgeon working in a high-volume
parathyroid surgery centre (grade C recommendation,
GRADE: high, ‘⊕⊕⊕⊕’).
& Levels IVand Vevidence supports that recurrent and per-
sistence pHPT occurs more frequently in patients with
double adenomas. Hence, in situations where a double
adenoma has been identified, the surgeon should have a
high index of suspicion during surgery and postoperative-
ly for the possibility of four-gland disease (grade C rec-
ommendation, GRADE: moderate, ⊕⊕⊕O).
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